'Sirna' diaporamas de présentation

Roger Kaspar TransDerm rogerkaspar@transderm

Dundee Patient Support Meeting On the road to the clinic: Development of siRNA-based therapeutics for PC. Roger Kaspar TransDerm rogerkaspar@transderm.org. PC is what we call a dominant negative genetic disorder. Translation. Bad keratin. Good keratin. Translation.

513 views • 41 slides

Nucleotide-based therapeutic agents

Nucleotide-based therapeutic agents. MAJOR DRAWBACKS OF ANTISENSE OLIGONUCLEOTIDES. Biologic instability. MAJOR DRAWBACKS OF ANTISENSE OLIGONUCLEOTIDES. Biologic instability Cellular targeting Uptake Efflux from endosomes. MAJOR DRAWBACKS OF ANTISENSE OLIGONUCLEOTIDES.

391 views • 29 slides

Whole-genome approach to highly specific siRNA design by CRM

Whole-genome approach to highly specific siRNA design by CRM (Comprehensive Redundancy Minimizer) Algorith m. Tariq Alsheddi, Leonid Vasin & Ancha Baranova George Mason University USA. Presented by Prof. Vikas Chandhoke. siRNA. Introduction:

381 views • 26 slides

2006 ?????? RNA Interference

2006 ?????? RNA Interference. ?? : ??? ?? :B9602026 ??? ?? :B9602006 ??? B9602009 ??? B9602034 ??? B9602042 ???. ????. 1990- ???????? co-supression ??? 1994- co-supression ??????????????? ? Post-transcriptional Gene Silencing ???

534 views • 25 slides

RNA interference in specific gene silencing ('knockdown')

RNA interference in specific gene silencing ('knockdown'). Christopher V. Jones Jason Carter. RNA Interference. mRNA transcribed from DNA encodes for a protein expressed by a certain gene

461 views • 19 slides

Transfection of eukaryotic cells

Transfection of eukaryotic cells. Bryon Anderson. Presentation Overview. What is Transfection? Transfection vs. Transformation Purpose of Transfection How it Works Experimental method/process Strengths and weaknesses of technique. Transfection. What is Transfection?

2.77k views • 18 slides

BCL-X L siRNA Drug Dose Response Curves

Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies. BCL-X L siRNA Drug Dose Response Curves. Supplementary Figure 1A. Supplementary Figure 1B,C. B. TF-1.

356 views • 16 slides

RNAi nterference ( RNAi )

426 views • 15 slides

339 views • 14 slides

miRNA :

miRNA :. microRNA. siRNA :. small interfering RNA. https:// openi.nlm.nih.gov / detailedresult.php?img =PMC3395882_fgene-03-00132-g001&req=4.

451 views • 13 slides

Cortical plaques

259 views • 12 slides

A Basic Introduction to SFold

A Basic Introduction to SFold. Kevin MacDonald December 7, 2004 BI420 Final Presentation. Introduction to Gene Knockout. One method of studying gene expression and function is through gene knockout. In this process the targeted gene is silenced (inactivated) and the results are studied.

246 views • 10 slides

New approaches for determining functional siRNA

New approaches for determining functional siRNA. Liyang Diao Dr. Stanley Dunn, advisor. mRNA. protein. DNA. Protein Production. Production of proteins starts with DNA DNA is in the nucleus Requires mRNA to finish protein production mRNA: messenger RNA RNAi: RNA interference

166 views • 8 slides

Pavithra et al., Figure S1

23 Kb. Exon 2. Exon 14. Exon 1. cc cgacaaacacg gtcg cagaaac. FP1. 2R. For. Rev. f 1. ATG. Exon 14. Exon 1. Exon 2. f 17. PGA2. Unt. f 1. f 17. Actin. 1. 2. Time (h). 24. 12. 6. 16. 0. f 1. f 17. Actin. A. B. C. Pavithra et al., Figure S1. A. B. - PGA2.

128 views • 4 slides

146 views • 4 slides

HBO1 siRNA #2

Supplementary Figure 1. A. E. C. HeLa cells. control siRNA. Whole cell extracts. Chromatin fractions. Input (5%). IP : HBO1. IP : IgG. %G1/G0 %S %G2/M. 41.70 26.56 31.74. -. -. -. -. +. +. HBO1 siRNA #2. 200. Number of cells. -. -. -. -. +. +. Control siRNA. 100.

128 views • 1 slides

SIRT-1 /18S

A. *. *. *. SIRT-1 /18S. siRNA negative control. Control. siRNA. siRNA leucine. B. C. *. *. *. *. *. *. PGC-1 ? /18S. NRF /18S. Control. siRNA negative control. siRNA. siRNA leucine. Control. siRNA negative control. siRNA leucine. siRNA.

121 views • 1 slides

2 siRNA

DNAPK siRNA. A. 2 siRNA. Control. C. ii). 120. i). B. AA8 control. 100. CHOV3 DNAPK-/-. 80. [ 35 S]-Met Incorporation %. [ 35 S]-Met Incorporation %. 60. 40. 20. 0. Time (h). Time (h). A reduction in DNA-PKcs by RNAi also prevents translational inhibition

188 views • 1 slides

High Content Analysis (HCA)

201 views • 1 slides

Cat # SL100570 Store at 4 0 C

111 views • 1 slides